LIMN
Liminatus Pharma, Inc. Class A Common Stock
NASDAQ · Healthcare · Biotechnology · US
$3.71
+0.27%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-4165.9%
Return on equity
-367.9%
Return on assets
-233.2%
Return on invested capital
0.00x
Asset turnover
-$4.0M
Cash from operations
$2.25
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026